Objective: To observe the effect of Xuezhikang capsule on insulin resistance in overweight patients with newly diagnosed type 2 diabetes (T2DM). Method: Sixty cases of patients both with newly diagnosed type 2 diabetes and overweight were randomly divided into two groups. The control group received therapy with metformin 0.5 g once

three times daily. The observation group received Xuezhikang capsule

0.6 g once

two times daily based on the treatment in control group. Both groups were given continuous medication for 3 months. Fasting blood-glucose (FBG)

fasting insulin (FINS)

glycosylated hemoglobin A1c (HbA1c)

interleukin-1(IL-1)

interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were tested both before and after treatment

and body mass index (BMI) and insulin resistance index (HMOA-IR) were calculated. Taking HbA1c<6.5% as the successful control level of blood glucose

glucose-target-rate was calculated after treatment in both groups. Result: After 3 months of treatment

the levels of BMI

FBG

FINS

HOMA-IR

HbA1c

IL-1

IL-6

TNF-α of both groups were decreased than before (P<0.05)

and the levels of FBG

FINS

HOMA-IR

IL-1

IL-6

TNF-α of observation group were lower than those in control group (P<0.0 5)

but the levels of HbA1c and BMI had no significant difference between two groups

and the difference values of FBG

FINS

HbA1c

HOMA-IR

IL-1

IL-6

and TNF-α before and after treatment in observation group were higher than those in control group (P<0.0 5)

and the difference value of BMI before and after treatment showed no significant difference between two groups. Glucose-target-rate was 80.0% (24/30) for the patients in observation group and it was higher than 66.7%(20/30) in control group

but there was no statistically significant difference. Conclusion: Xuezhikang capsule can improve insulin resistance in obese patients with newly diagnosed type 2 diabetes and reduce the inflammation reaction.